MA40225A - Composés dihydroisoquinolinone substitués - Google Patents
Composés dihydroisoquinolinone substituésInfo
- Publication number
- MA40225A MA40225A MA040225A MA40225A MA40225A MA 40225 A MA40225 A MA 40225A MA 040225 A MA040225 A MA 040225A MA 40225 A MA40225 A MA 40225A MA 40225 A MA40225 A MA 40225A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- salts
- well
- substituted
- substituted dihydroisoquinolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
La présente invention concerne des composés de formule générale (i) dans laquelle r1, r2, r3, r4, l, x et z sont tels que définis ici, ainsi que leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques comprenant ces composés et sels, ainsi que des procédés d'utiliser de tels composés, sels et compositions pour le traitement de la croissance cellulaire anormale, y compris le cancer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013410P | 2014-06-17 | 2014-06-17 | |
| US201562156533P | 2015-05-04 | 2015-05-04 | |
| EP15730290.2A EP3157915B1 (fr) | 2014-06-17 | 2015-06-05 | Composés dihydroisoquinolinone substitués |
| PCT/IB2015/054272 WO2015193765A1 (fr) | 2014-06-17 | 2015-06-05 | Composés dihydroisoquinolinone substitués |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40225A true MA40225A (fr) | 2019-02-27 |
| MA40225B1 MA40225B1 (fr) | 2019-05-31 |
Family
ID=53434412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40225A MA40225B1 (fr) | 2014-06-17 | 2015-06-05 | Composés dihydroisoquinolinone substitués |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US9481666B2 (fr) |
| EP (2) | EP3521285A1 (fr) |
| JP (1) | JP6152495B1 (fr) |
| KR (1) | KR101877187B1 (fr) |
| CN (1) | CN107207464B (fr) |
| AP (1) | AP2016009605A0 (fr) |
| AU (1) | AU2015275826B2 (fr) |
| BR (1) | BR112016029612B1 (fr) |
| CA (1) | CA2894298C (fr) |
| CL (1) | CL2016003246A1 (fr) |
| CR (2) | CR20200484A (fr) |
| CU (1) | CU24408B1 (fr) |
| CY (1) | CY1121706T1 (fr) |
| DK (1) | DK3157915T3 (fr) |
| EA (1) | EA031892B1 (fr) |
| ES (1) | ES2721031T3 (fr) |
| GE (1) | GEP20186933B (fr) |
| HR (1) | HRP20190604T1 (fr) |
| HU (1) | HUE042964T2 (fr) |
| IL (1) | IL248991B (fr) |
| LT (1) | LT3157915T (fr) |
| MA (1) | MA40225B1 (fr) |
| MD (1) | MD4820C1 (fr) |
| ME (1) | ME03419B (fr) |
| MX (1) | MX2016016764A (fr) |
| MY (1) | MY185765A (fr) |
| NZ (1) | NZ726108A (fr) |
| PE (1) | PE20161552A1 (fr) |
| PH (1) | PH12016502378A1 (fr) |
| PL (1) | PL3157915T3 (fr) |
| PT (1) | PT3157915T (fr) |
| RS (1) | RS58632B1 (fr) |
| SG (1) | SG11201609386YA (fr) |
| SI (1) | SI3157915T1 (fr) |
| SV (1) | SV2016005333A (fr) |
| TN (1) | TN2016000529A1 (fr) |
| TW (1) | TWI561516B (fr) |
| UA (1) | UA118380C2 (fr) |
| UY (1) | UY36170A (fr) |
| WO (1) | WO2015193765A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| AU2017260854B2 (en) | 2016-05-05 | 2020-01-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| EP3655392A1 (fr) | 2017-07-17 | 2020-05-27 | Abbvie Deutschland GmbH & Co. KG | Composés de quinoléine à substitution en positions 1, 2, 3 et 4 utilisés en tant que modulateurs de s1p |
| BR112020008325A2 (pt) * | 2017-11-14 | 2020-10-20 | Pfizer Inc. | terapias de combinação com o inibidor de ezh2 |
| KR102451529B1 (ko) | 2018-01-31 | 2022-10-06 | 미라티 테라퓨틱스, 인크. | Prc2 억제제 |
| AU2019255310B2 (en) | 2018-04-18 | 2022-11-24 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| WO2020086857A1 (fr) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Modulateurs et inhibiteurs de wdr5 |
| KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| WO2022018594A1 (fr) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthèse de nouveaux intermédiaires pour 3,4-dihydroisoquinolinones substituées |
| WO2022122037A1 (fr) * | 2020-12-11 | 2022-06-16 | 上海奕拓医药科技有限责任公司 | Dérivé de dihydroisoquinolinone et son application |
| WO2023098880A1 (fr) * | 2021-12-02 | 2023-06-08 | 上海翰森生物医药科技有限公司 | Dérivé de cycle fusionné, son procédé de préparation et son application |
| WO2023111810A1 (fr) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Polythérapies et leurs utilisations pour le traitement du cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| WO2007075783A2 (fr) * | 2005-12-22 | 2007-07-05 | Wyeth | Isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones et 1,4-dihydro-3(2h)-isoquinolones et procedes d'utilisation correspondant |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| CA2726508C (fr) * | 2008-06-17 | 2016-06-07 | Astrazeneca Ab | Composes pyridines |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| EP2566327B1 (fr) | 2010-05-07 | 2017-03-29 | Glaxosmithkline LLC | Indoles |
| US8895245B2 (en) | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
| WO2012035078A1 (fr) | 2010-09-16 | 2012-03-22 | Novartis Ag | Inhibiteurs de la 17α-hydroxylase/c17,20-lyase |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2012118812A2 (fr) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Composés hétéroaryles bicycliques substitués condensés en 6,5 |
| TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR20140082742A (ko) | 2011-09-30 | 2014-07-02 | 글락소스미스클라인 엘엘씨 | 암을 치료하는 방법 |
| WO2013059944A1 (fr) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Régulateurs épigénétiques et utilisations associées |
| WO2013173441A2 (fr) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Inhibiteurs d'homologue d'activateur de zeste 2 |
| CA2884848C (fr) | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Composes de benzamide et heterobenzamide |
| FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
| AU2013363768B2 (en) | 2012-12-21 | 2016-02-04 | F. Hoffmann-La Roche Ag | Peptides as oxytocin agonists |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| PL2935222T3 (pl) | 2012-12-21 | 2019-02-28 | Epizyme Inc | Inhibitory PRMT5 i ich zastosowania |
| MY191741A (en) | 2012-12-21 | 2022-07-13 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| LT2934568T (lt) | 2012-12-21 | 2018-02-12 | Sanofi | Dvigubi glp1/gip arba trigubi glp/gip/gliukagono agonistai |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2015
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/fr unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/fr not_active Withdrawn
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/fr active Active
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active IP Right Grant
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/fr active Application Filing
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 CA CA2894298A patent/CA2894298C/fr active Active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-03-28 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA45920A (fr) | Inhibiteurs de pyridopyrimidinone cdk2/4/6 | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA44721B1 (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MA38175A1 (fr) | Lactames fusionnés à un aryle et hétéroaryle | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
| MA39777A (fr) | Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| EP4316591A3 (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique |